Uwe Hillen1, Ulrike Leiter2, Sylvie Haase3, Roland Kaufmann4, Jürgen Becker5, Ralf Gutzmer6, Patrick Terheyden7, Albrecht Krause-Bergmann8, Hans-Joachim Schulze9, Jessica Hassel10, Nina Lahner11, Uwe Wollina12, Fabian Ziller13, Jochen Utikal14, Christine Hafner15, Jens Ulrich16, Hans-Günther Machens17, Carsten Weishaupt18, Axel Hauschild19, Peter Mohr20, Claudia Pföhler21, Jan Maurer22, Patrick Wolff23, Christine Windemuth-Kieselbach23, Dirk Schadendorf24, Elisabeth Livingstone25. 1. Department of Dermatology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany; Department of Dermatology and Venerology, Vivantes Klinikum Neukölln, 12351 Berlin, Germany. Electronic address: uwe.hillen@vivantes.de. 2. Department of Dermatology, University Hospital Tübingen, 72076 Tübingen, Germany. 3. Department of Dermatology, University Hospital Frankfurt, 60590 Frankfurt, Germany; Hautärzte in Konstanz, 78462 Konstanz, Germany. 4. Department of Dermatology, University Hospital Frankfurt, 60590 Frankfurt, Germany. 5. Department of Dermatology, University Hospital Graz, 8036 Graz, Austria; Translational Skin Cancer Research, German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany. 6. Skin Cancer Center, Department of Dermatology and Allergy, Hannover Medical School, 30625 Hannover, Germany. 7. Department of Dermatology, University Hospital Schleswig-Holstein, Campus Lübeck, 23538 Lübeck, Germany. 8. Department of Plastic Surgery, Fachklinik Hornheide, 48157 Münster, Germany. 9. Department of Dermatology, Fachklinik Hornheide, 48157 Münster, Germany. 10. Department of Dermatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. 11. Department of Dermatology, Ruhr-University Bochum, 44791 Bochum, Germany. 12. Department of Dermatology, University Hospital Dresden, 01067 Dresden, Germany. 13. Department of Dermatology, DRK Krankenhaus Rabenstein, 09117 Chemnitz, Germany. 14. Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany. 15. Dept. of Dermatology, University Hospital St. Pölten, Karl Landsteiner University of Health Sciences, 3500 St. Pölten, Austria; Karl Landsteiner Institute of Dermatological Research, Karl Landsteiner Gesellschaft, 3500 St. Pölten, Austria. 16. Department of Dermatology, Harzklinikum Dorothea Christiane Erxleben, 06484 Quedlinburg, Germany. 17. Department of Plastic Surgery and Hand Surgery, Klinikum Rechts der Isar, Technische Universität München, 81675 Munich, Germany. 18. Department of Dermatology, University Hospital Münster, 48149 Münster, Germany. 19. Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany. 20. Department of Dermatology, Elbe-Kliniken, 21614 Buxtehude, Germany. 21. Department of Dermatology, Saarland University Medical School, 66421 Homburg/Saar, Germany. 22. Department of ENT, Katholisches Klinikum Marienhof, 56073 Koblenz, Germany. 23. Alcedis GmbH, Medical Research Institute, 35394 Gießen, Germany. 24. Department of Dermatology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany; Translational Skin Cancer Research, German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany. 25. Department of Dermatology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.
Abstract
BACKGROUND: Advanced cutaneous squamous cell carcinoma (aSCC) is an area of unmet medical need and no treatment standards are established. Recently, an anti-PD-1 inhibitor received FDA breakthrough therapy designation. The aim of the study was to describe the clinical course, therapeutic management and prognosis of aSCC under real-life conditions. PATIENTS AND METHODS: In a retrospective study performed in 24 German and Austrian hospitals and doctor's offices, patient and tumour characteristics of patients diagnosed with aSCC between January 1, 2010 and December 31, 2011 and their disease course was documented. Advanced SCC comprised either locally advanced SCCs (laSCC) or metastatic SCCs (mSCC) with any kind of metastatic spread. RESULTS: Data of 190 patients with aSCC were analysed. Median age at time of diagnosis of aSCC was 78 years. LaSCC was diagnosed in 76 patients (40%), 114 patients (60%) had mSCC. Once diagnosed with laSCC, most patients (59%) did not receive any therapy, whereas in 92% of mSCC patients at least one type of therapy was performed. Only 32 patients (29 mSCC, 3 laSCC) received systemic antitumour therapies, mostly EGFR inhibitor-based regimens. Mean duration of response was short (17-months laSCC patients, 3-months mSCC patients). Only 2 patients achieved a complete response, 27% had a partial response, 43% disease stabilisation. At diagnosis of aSCC, ECOG status was 0-1 in most patients. Non-malignant comorbidities influenced the decision on SCC-specific therapy in 39 patients (21%). CONCLUSIONS: Our data show the high medical need for efficient and tolerable antitumour therapies and demonstrate that despite older age and comorbidities, most patients can be expected to be fit for treatment. This study provides a historical context for emerging aSCC treatments.
BACKGROUND: Advanced cutaneous squamous cell carcinoma (aSCC) is an area of unmet medical need and no treatment standards are established. Recently, an anti-PD-1 inhibitor received FDA breakthrough therapy designation. The aim of the study was to describe the clinical course, therapeutic management and prognosis of aSCC under real-life conditions. PATIENTS AND METHODS: In a retrospective study performed in 24 German and Austrian hospitals and doctor's offices, patient and tumour characteristics of patients diagnosed with aSCC between January 1, 2010 and December 31, 2011 and their disease course was documented. Advanced SCC comprised either locally advanced SCCs (laSCC) or metastatic SCCs (mSCC) with any kind of metastatic spread. RESULTS: Data of 190 patients with aSCC were analysed. Median age at time of diagnosis of aSCC was 78 years. LaSCC was diagnosed in 76 patients (40%), 114 patients (60%) had mSCC. Once diagnosed with laSCC, most patients (59%) did not receive any therapy, whereas in 92% of mSCC patients at least one type of therapy was performed. Only 32 patients (29 mSCC, 3 laSCC) received systemic antitumour therapies, mostly EGFR inhibitor-based regimens. Mean duration of response was short (17-months laSCCpatients, 3-months mSCC patients). Only 2 patients achieved a complete response, 27% had a partial response, 43% disease stabilisation. At diagnosis of aSCC, ECOG status was 0-1 in most patients. Non-malignant comorbidities influenced the decision on SCC-specific therapy in 39 patients (21%). CONCLUSIONS: Our data show the high medical need for efficient and tolerable antitumour therapies and demonstrate that despite older age and comorbidities, most patients can be expected to be fit for treatment. This study provides a historical context for emerging aSCC treatments.
Authors: Michael R Migden; Nikhil I Khushalani; Anne Lynn S Chang; Karl D Lewis; Chrysalyne D Schmults; Leonel Hernandez-Aya; Friedegund Meier; Dirk Schadendorf; Alexander Guminski; Axel Hauschild; Deborah J Wong; Gregory A Daniels; Carola Berking; Vladimir Jankovic; Elizabeth Stankevich; Jocelyn Booth; Siyu Li; David M Weinreich; George D Yancopoulos; Israel Lowy; Matthew G Fury; Danny Rischin Journal: Lancet Oncol Date: 2020-01-14 Impact factor: 41.316
Authors: C Lance Cowey; Nicholas J Robert; Janet L Espirito; Kalatu Davies; Jennifer Frytak; Israel Lowy; Matthew G Fury Journal: Cancer Med Date: 2020-06-24 Impact factor: 4.452
Authors: Renata Ferrarotto; Moran Amit; Priyadharsini Nagarajan; M Laura Rubin; Ying Yuan; Diana Bell; Adel K El-Naggar; Jason M Johnson; William H Morrison; David I Rosenthal; Bonnie S Glisson; Faye M Johnson; Charles Lu; Frank E Mott; Bita Esmaeli; Eduardo M Diaz; Paul W Gidley; Ryan P Goepfert; Carol M Lewis; Randal S Weber; Jennifer A Wargo; Sreyashi Basu; Fei Duan; Shalini S Yadav; Padmanee Sharma; James P Allison; Jeffrey N Myers; Neil D Gross Journal: Clin Cancer Res Date: 2021-06-29 Impact factor: 12.531